Liver Cancer Clinical Trials

Clinical trials are research studies that involve people. The clinical trials on this list are for liver cancer. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 213
< Previous 1 2 3 4 5 ... 9 Next >

  • DKN-01 and Nivolumab for the Treatment of Advanced Biliary Tract Cancer

    This phase II trial studies how well DKN-01 and nivolumab work in treating patients with biliary tract cancer that has spread to other places in the body (advanced). DKN-01 and nivolumab are both antibodies. An antibody is a protein that attaches to other cells to fight off infection. DKN-01 may work by attaching to and inhibiting (stopping) a specific pathway in your cells that is responsible for processes such as cell growth. Nivolumab may work by attaching to and inhibiting a specific protein in your cancer that controls parts of your immune system (the system in your body that fights off infections and diseases) by shutting down certain immune responses. Nivolumab may inhibit the protein, thus allowing immune cells to recognize and destroy cancer cells. Giving DKN-01 and nivolumab may work better in treating patients with advanced biliary tract cancer.
    Location: 3 locations

  • Phase 1 / 2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

    TC-210 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1 / 2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently determine an overall response rate in patients with advanced mesothelin-expressing cancers.
    Location: 5 locations

  • Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

    This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
    Location: 4 locations

  • A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

    This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced HCC.
    Location: 3 locations

  • TCR-engineered T Cells in Solid Tumors

    The study purpose is to establish the safety and tolerability of IMA203 product in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
    Location: 3 locations

  • Durvalumab, Tremelimumab, and Radiation Therapy in Treating Participants with Unresectable, Locally Advanced, or Metastatic Hepatocellular Carcinoma or Biliary Tract Cancer

    This phase II trial studies how well durvalumab, tremelimumab, and radiation therapy work in treating participants with hepatocellular carcinoma or biliary tract cancer that can't be removed via surgery or that has spread to other parts of the body. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving durvalumab, tremelimumab, and radiation therapy may work better than radiation therapy alone in treating participants with hepatocellular carcinoma or biliary tract cancer.
    Location: 3 locations

  • TCR-engineered T Cells in Solid Tumors: IMA202-101

    The study purpose is to establish the safety and tolerability of IMA202 product in patients with solid tumors that express melanoma-associated antigen 1 (MAGEA1).
    Location: 3 locations

  • Percutaneous Ablation or Hypofractionated Image-Guided Radiation Therapy in Improving Quality of Life in Participants with Liver Cancer

    This phase II trial compares how well percutaneous local ablation or hypofractionated image-guided radiation therapy works in improving quality of life in participants with liver cancer. Percutaneous ablation works by inserting special needles into the liver tumor and using microwaves or radiowaves to damage tumor cells in a way that may cause cell death. Hypofractionated image-guided radiation therapy is a type of external radiation therapy where beams of radiation enter the liver from multiple angles to treat the liver cancer over several treatment sessions and may cause less damage to nearby healthy tissue. It is not yet known whether percutaneous local ablation or stereotactic body radiation therapy works better in improving the quality of life in participants with liver cancer.
    Location: 3 locations

  • A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

    This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
    Location: 3 locations

  • Nivolumab and Drug Eluting Bead Transarterial Chemoembolization in Treating Patients with Liver Cancer

    This early phase I trial studies the side effects of nivolumab when given together with drug eluting bead transarterial chemoembolization in treating patients with liver cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drug eluting bead transarterial chemoembolization is a procedure where doctors put a needle through the skin into a major artery in the groin or arm followed by the insertion of a catheter that delivers small beads to block blood flow to the liver tumor. Giving nivolumab and chemoembolization may help shrink or kill liver tumors and allow people to live longer with liver cancer.
    Location: 6 locations

  • Pembrolizumab and Yttrium-90 Microsphere Radioembolization in Treating Patients with Locally Advanced Liver Cancer

    This early phase I trial studies how well pembrolizumab and yttrium-90 microsphere radioembolization work in treating patients with liver cancer that usually cannot be cured or controlled with treatment but has not spread to other places outside liver (locally advanced). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radioembolization kills tumor cells by carrying radiation drugs directly into blood vessels near the tumors and then blocking the blood flow to allow a higher concentration of the drug to reach the tumor for a longer period of time. Radioembolization may cause fewer side effects in treating patients with liver cancer. Pembrolizumab and yttrium-90 microsphere radioembolization may work better in treating patients with liver cancer.
    Location: 3 locations

  • Pembrolizumab and Hsp90 inhibitor XL888 in Treating Patients with Advanced Gastrointestinal Cancer

    This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body. Hsp90 inhibitor XL888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving Hsp90 inhibitor XL888 with pembrolizumab may work better in treating patients with gastrointestinal cancer.
    Location: 3 locations

  • Paediatric Hepatic International Tumour Trial

    The PHITT trial is an over-arching study for patients with Hepatoblastoma (HB) and Hepatocellular Carcinoma (HCC). This trial will use a risk-adapted approach to the treatment of children diagnosed with HB. Children with HCC will be included as a separate cohort.
    Location: 3 locations

  • Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced / Metastatic Solid Tumors

    The purpose of this study is to assess the safety and tolerability of BJ-001, a human IL-15 fusion protein, administered via subcutaneous injections, as a single agent and in combination with PD-1 or PD-L1 Inhibitor in adult patients with Locally Advanced / Metastatic Solid Tumors
    Location: 2 locations

  • GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

    This is a single-arm, open-label, multi-site Phase I / IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.
    Location: 2 locations

  • Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced / Metastatic Solid Tumors

    A multicenter open-label phase 1 / 1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced / metastatic solid tumors
    Location: 2 locations

  • Testing the Combination of New Anti-cancer Drug Nedisertib with Avelumab and Radiation Therapy for Advanced / Metastatic Solid Tumors and Hepatobiliary Malignancies

    This phase I / II trial studies the best dose and side effects of nedisertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies that have spread to other places in the body (advanced / metastatic). Nedisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving nedisertib in combination with avelumab and hypofractionated radiation therapy may work better than other standard chemotherapy, hormonal, targeted, or immunotherapy medicines available in treating patients with solid tumors and hepatobiliary malignancies.
    Location: 2 locations

  • FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

    FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in subjects with advanced solid tumors.
    Location: 3 locations

  • Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors

    The study will determine the recommended Phase 2 dose (RP2D) of ABBV-151 administered as monotherapy and in combination with ABBV-181 as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-151 alone and in combination with ABBV-181. The study will consist of 2 phases: dose escalation and dose expansion.
    Location: 3 locations

  • Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080 / MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005 / E7080-G000-224 / LEAP-005)

    The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080 / MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), or biliary tract cancers (BTC). Participants will be enrolled into initial tumor-specific cohorts which will be expanded if adequate efficacy is determined.
    Location: 4 locations

  • Ablation Confirmation Study

    Prospective, single-arm, multicenter study that will generate clinical data using the NEUWAVE MicroWave Ablation System with AC (Ablation Confirmation) software in patients undergoing ablation of a soft tissue liver lesion.
    Location: 3 locations

  • This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer

    A first-in-human open-label, Phase I / II study to evaluate the safety, tolerability, MTD / RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent in patients with solid tumors, hepatocellular carcinomas (HCC), and castrate-resistant prostate cancer (CRPC).
    Location: 2 locations

  • Sorafenib and Pembrolizumab in Treating Patients with Advanced or Metastatic Liver Cancer

    This phase Ib / II trial studies how well sorafenib and pembrolizumab work in treating patients with liver cancer that has spread to other parts of the body (advanced or metastatic). Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving sorafenib and pembrolizumab may work better in treating patients with liver cancer.
    Location: 2 locations

  • Stereotactic Body Radiation Therapy and Nivolumab with or without Ipilimumab in Treating Patients with Unresectable Liver Cancer

    This phase I trial studies the side effects of stereotactic body radiation therapy and nivolumab with or without ipilimumab in treating patients with liver cancer that cannot be removed by surgery. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy, nivolumab and ipilimumab may work better at treating liver cancer.
    Location: 2 locations

  • CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

    This is a multicenter, open-label, phase 1b study of CBP501 / cisplatin / nivolumab combination administered once every 21 days to patients with advanced solid tumors.
    Location: 2 locations


< Previous 1 2 3 4 5 ... 9 Next >